Rationale for full-season dosing for passive antibody prophylaxis of respiratory syncytial virus

Area of Science:

• Pediatric Infectious Diseases
• Neonatology
• Pharmacokinetics and Immunology

Background:

• Palivizumab is recommended for preventing severe respiratory syncytial virus (RSV) disease in preterm infants (≤ 35 weeks gestational age).
• Current guidelines sometimes suggest discontinuing palivizumab mid-season, potentially leaving infants vulnerable.
• The optimal duration of palivizumab prophylaxis remains a critical clinical question.

Purpose of the Study:

• To evaluate the necessity of full-season palivizumab dosing in preterm infants.
• To assess the risk of respiratory syncytial virus hospitalization (RSVH) based on chronological age.
• To review palivizumab's pharmacokinetic properties in relation to protective levels and dosing duration.

Main Methods:

• Review of pharmacokinetic data for palivizumab.
• Analysis of clinical trial data on palivizumab serum trough concentrations and interpatient variability.
• Examination of RSVH risk stratified by infant chronological age, particularly for late-preterm infants.

Main Results:

• Precise protective serum concentrations of palivizumab in humans have not been definitively established.
• Significant variability exists in palivizumab serum trough concentrations among patients.
• Partial-season dosing is linked to an increased risk of RSVH, with risk remaining elevated through at least six months of age for late-preterm infants.

Conclusions:

• Full-season, monthly palivizumab dosing is the only empirically validated method to prevent RSVH.
• Late-preterm infants face a substantial risk of RSVH up to at least six months of age.
• Continuous palivizumab prophylaxis throughout the RSV season is beneficial for this high-risk population.